BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32204058)

  • 1. Silencing KLK12 expression via RGDfC-decorated selenium nanoparticles for the treatment of colorectal cancer in vitro and in vivo.
    Xia Y; Tang G; Guo M; Xu T; Chen H; Lin Z; Li Y; Chen Y; Zhu B; Liu H; Cao J
    Mater Sci Eng C Mater Biol Appl; 2020 May; 110():110594. PubMed ID: 32204058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functionalized selenium nanoparticles for targeted siRNA delivery silence Derlin1 and promote antitumor efficacy against cervical cancer.
    Xia Y; Tang G; Wang C; Zhong J; Chen Y; Hua L; Li Y; Liu H; Zhu B
    Drug Deliv; 2020 Dec; 27(1):15-25. PubMed ID: 31830840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of MEF2D by siRNA Loaded Selenium Nanoparticles for Ovarian Cancer Therapy.
    Wang C; Xia Y; Huo S; Shou D; Mei Q; Tang W; Li Y; Liu H; Zhou Y; Zhu B
    Int J Nanomedicine; 2020; 15():9759-9770. PubMed ID: 33304100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy.
    Xia Y; Chen Y; Hua L; Zhao M; Xu T; Wang C; Li Y; Zhu B
    Int J Nanomedicine; 2018; 13():6929-6939. PubMed ID: 30464451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy.
    Xia Y; Xu T; Wang C; Li Y; Lin Z; Zhao M; Zhu B
    Int J Nanomedicine; 2018; 13():143-159. PubMed ID: 29317822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering siRNA-loaded and RGDfC-targeted selenium nanoparticles for highly efficient silencing of DCBLD2 gene for colorectal cancer treatment.
    Huang H; Chen H; Shou D; Quan Y; Cheng J; Chen H; Ning G; Li Y; Xia Y; Zhou Y
    Discov Nano; 2023 Jul; 18(1):94. PubMed ID: 37477789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-targeted delivery of siRNA to silence Sox2 gene expression enhances therapeutic response in hepatocellular carcinoma.
    Xia Y; Tang G; Chen Y; Wang C; Guo M; Xu T; Zhao M; Zhou Y
    Bioact Mater; 2021 May; 6(5):1330-1340. PubMed ID: 33210026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of siRNA using RGDfC-conjugated functionalized selenium nanoparticles for anticancer therapy.
    Xia Y; Lin Z; Li Y; Zhao M; Wang C; Guo M; Zhang B; Zhu B
    J Mater Chem B; 2017 Sep; 5(33):6941-6952. PubMed ID: 32264343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of HES5-siRNA with novel polypeptide-modified nanoparticles for hepatocellular carcinoma therapy.
    Xia Y; Wang C; Xu T; Li Y; Guo M; Lin Z; Zhao M; Zhu B
    RSC Adv; 2018 Jan; 8(4):1917-1926. PubMed ID: 35542585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy.
    Xia Y; Guo M; Xu T; Li Y; Wang C; Lin Z; Zhao M; Zhu B
    Int J Nanomedicine; 2018; 13():1539-1552. PubMed ID: 29588583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy.
    Xia Y; Xiao M; Zhao M; Xu T; Guo M; Wang C; Li Y; Zhu B; Liu H
    Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110100. PubMed ID: 31753388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Xia Y; Zhong J; Zhao M; Tang Y; Han N; Hua L; Xu T; Wang C; Zhu B
    Drug Deliv; 2019 Dec; 26(1):1-11. PubMed ID: 31928356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of pH-sensitive functional selenium nanoparticles shows enhanced in vivo VEGF-siRNA silencing and fluorescence imaging.
    Yu Q; Liu Y; Cao C; Le F; Qin X; Sun D; Liu J
    Nanoscale; 2014 Aug; 6(15):9279-92. PubMed ID: 24986368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy.
    Zou J; Su S; Chen Z; Liang F; Zeng Y; Cen W; Zhang X; Xia Y; Huang D
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3456-3464. PubMed ID: 31469318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance.
    Zheng W; Cao C; Liu Y; Yu Q; Zheng C; Sun D; Ren X; Liu J
    Acta Biomater; 2015 Jan; 11():368-80. PubMed ID: 25204523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifunctional selenium nanoparticles as carriers of HSP70 siRNA to induce apoptosis of HepG2 cells.
    Li Y; Lin Z; Zhao M; Xu T; Wang C; Xia H; Wang H; Zhu B
    Int J Nanomedicine; 2016; 11():3065-76. PubMed ID: 27462151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
    Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
    Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of tumor growth and vasculature and fluorescence imaging using functionalized ruthenium-thiol protected selenium nanoparticles.
    Sun D; Liu Y; Yu Q; Qin X; Yang L; Zhou Y; Chen L; Liu J
    Biomaterials; 2014 Feb; 35(5):1572-83. PubMed ID: 24268198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selenium nanoparticles coated with pH responsive silk fibroin complex for fingolimod release and enhanced targeting in thyroid cancer.
    Zou X; Jiang Z; Li L; Huang Z
    Artif Cells Nanomed Biotechnol; 2021 Dec; 49(1):83-95. PubMed ID: 33438446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy.
    Liu L; Liu X; Xu Q; Wu P; Zuo X; Zhang J; Deng H; Wu Z; Ji A
    Int J Nanomedicine; 2014; 9():3509-26. PubMed ID: 25114522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.